[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364087-105":59,"doc-detail-364087-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-response-assessment-from-circulating-tumor-dna-in-patients-with-ovarian-cancer-treated-with-the-wee1-inhibitor-azenosertib","Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib","","Molecular response (MR) based on circulating tumor DNA (ctDNA) is evaluated as an early biomarker of treatment efficacy in high-grade serous ovarian cancer (HGSOC), where clinical utility remains uncertain. Plasma cell-free DNA was collected at baseline and after the first and/or second cycle from 123 recurrent HGSOC patients treated with the WEE1 inhibitor azenosertib. MR was defined by a >50% reduction in TP53 variant allelic fraction at earliest evaluable on-treatment time, then compared with radiographic response, time to progression, and CA-125 dynamics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-response-assessment-from-circulating-tumor-dna-in-patients-with-ovarian-cancer-treated-with-the-wee1-inhibitor-azenosertib/364087/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-response-assessment-from-circulating-tumor-dna-in-patients-with-ovarian-cancer-treated-with-the-wee1-inhibitor-azenosertib/364087.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is molecular response (MR) defined in this study?","Question",{"text":112,"@type":113},"MR is defined as a reduction of TP53 variant allelic fraction by more than 50% at the earliest evaluable on-treatment time point.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinical and biomarker endpoints were compared with MR?",{"text":117,"@type":113},"MR was compared with radiographic response per RECIST v1.1, time to progression (TTP), and CA-125 dynamics.",{"name":119,"@type":110,"acceptedAnswer":120},"What did MR show regarding treatment outcomes in HGSOC?",{"text":121,"@type":113},"Molecular responders had higher objective response rates, greater tumor shrinkage, and significantly longer TTP than nonresponders, and MR often preceded the best overall response by several weeks.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364087,1790201142,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original Reports | Precision Medicine  \nMolecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib  \nJinkil Jeong, PhD1  ; Jianhui Ma, MD, PhD1  ; Mona Abed, PhD1; Heekyung Chung, PhD1; Doris Kim, BA1; Nandini Molden, PhD1;  \nDivya Rajendran, MS1; Changhwan Shim, BS1; Danielle D. Jandial, MD1; Fiona Simpkins, MD2  ; Funda Meric-Bernstam, MD3  ; Leslie M. Randall, MD4  ; Mark R. Lackner, PhD1; and Olivier Harismendy, PhD1   \nDOI [https://doi.org/10.1200/PO-25-00844](https://doi.org/10.1200/PO-25-00844)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Molecular response (MR) based on circulating tumor DNA (ctDNA) is emerging as a promising early biomarker of treatment efﬁcacy in solid tumors; however, its clinical utility in high-grade serous ovarian cancer (HGSOC) remains to be established. This study evaluates the potential predictive value of ctDNA-based MR in with patients HGSOC treated with the WEE1 inhibitor azenosertib. |\n| METHODS | Plasma cell-free DNA was collected at baseline and after the ﬁrst and/or second cycle of treatment from 123 patients with recurrent HGSOC enrolled in clinical trials of azenosertib (N 5 123) . Using the set samples evaluable by high throughput DNA sequencing, MR was deﬁned as a reduction of TP53 variant allelic fraction >50% at the earliest evaluable on-treatment time point. MR was compared with radiographic response per Response Evaluation Criteria in Solid Tumors v1.1, time to progression (TTP), and CA-125 dynamics. |\n| RESULTS | Molecular responders showed a higher objective response rate (P 5 .012, odds ratio 5 0.26), greater tumor shrinkage (P 5 5.1e-5, Kruskal-Wallis), and asigniﬁcantly longer TTP than nonresponders (TTP median 5.49 months v 2.69 months, P 5 3.8e-5, hazard ratios [HR] 5 0.43). MR was able to identify patients with prolonged survival among those having stable disease at the ﬁrst radiographic assessment (P 5 3.8e-3, HR 5 0.44), and their MR preceded the best overall response by several weeks. Accounting for matching collection time points, MR was evaluable in more patients than CA-125, 88%(102 of 116) versus 71%(85 of 116), respectively, leading to similar predictive value (HR 5 0.41 v 0.45, TTP evaluation) . |\n| CONCLUSION | Ourﬁndings support thevalidity and potential clinical utility of ctDNA-based MR as a minimally invasive, rapid, and reliable early surrogate end point in HGSOC. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted July 9, 2026  \nPublished August 26, 2026  \nJCO Precis Oncol 10:e2500844 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nConsidered a potential surrogate for clinical response, molecular response (MR) consists of changes in circulating biomarkers observed within the ﬁrst 1-3 cycles of treatment. MR may provide an early indication of antitumor activity and whether patients with stable disease (SD) are beneﬁting from treatment. In the context of experimental therapeutics for solid tumors, MR within the ﬁrst cycle of therapy may provide an early surrogate end point for efﬁcacy of the investigational treatment compared with later survival endpoints. MR has typically been evaluated retrospectively in clinical trials1 ,2 and is useful for decision making around the dose and activity of experimental anticancer agents. Pending prospective validation, MR could potentially offer datadriven opportunities to conduct early phase studies, plan  \nadditional arms evaluating alternate doses or combinations, explore indications or patient selection strategies without waiting for a full readout of the study, or support rapid endpoint assessment for drug approvals. While MR is not currently acceptable as an approval end point across solid tumor studies, it remains a valuable exploratory end point in early phase studies. For example, MR data may inform early signal for potential clinical activity of an i","cbCaisMcasDAdhc0","https://ap.wps.com/l/cbCaisMcasDAdhc0","pdf",692603,11,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"How is molecular response (MR) defined in this study?\",\"answer\":\"MR is defined as a reduction of TP53 variant allelic fraction by more than 50% at the earliest evaluable on-treatment time point.\"},{\"question\":\"Which clinical and biomarker endpoints were compared with MR?\",\"answer\":\"MR was compared with radiographic response per RECIST v1.1, time to progression (TTP), and CA-125 dynamics.\"},{\"question\":\"What did MR show regarding treatment outcomes in HGSOC?\",\"answer\":\"Molecular responders had higher objective response rates, greater tumor shrinkage, and significantly longer TTP than nonresponders, and MR often preceded the best overall response by several weeks.\"}]","Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib | PDF",1790155572,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb5c7429f72a80da45b28db4bdc46eb9.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28c251aac43d245c5d71f52158ef8673.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b14718a85a7bfd159f36f7f3ed298626.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53e1106206b8fcdc90b00a7897fec01d.webp",980,1311]